Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07849673 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Improving ILD Screening in Patients With RA and SSc Using EHR-Embedded CDS and PRO Tools

Study acronym: ILD-QUI
StatusNot Yet Recruiting
PhaseNot applicable
Started2026-09-30
View on ClinicalTrials.gov ↗
This is a quality improvement initiative that aims to find better ways to identify interstitial lung disease (ILD) early in people with rheumatoid arthritis (RA) or systemic sclerosis (SSc). ILD is a serious lung problem that can develop in these conditions but is often missed. The project will test whether tools built into the electronic health record (EHR), including symptom surveys that patients complete on a tablet and alerts that help doctors decide when lung testing is needed, can increase screening rates. About 16 rheumatology clinics that use the same EHR system will take part. All clinics will eventually use the new tools, but they will start at different times. This allows researchers to compare usual care to the new approach within each clinic. Adults with RA or SSc who have not previously been diagnosed with ILD and who have not had recent lung testing will be included automatically through their routine clinic visits. The study expects to include about 800 patients in total. The main question is whether more eligible patients receive recommended ILD screening, which includes either a pulmonary function test or a high-resolution CT scan, within seven days of their clinic visit. The study will also look at how often lung tests are ordered and completed, how often patients report symptoms such as shortness of breath or cough, and whether the alerts lead to real-time clinical decisions. This project lasts two years and uses information already collected during routine clinical care. No additional procedures or medications are required.
Trial Details
NCT Number NCT07849673
Lead Sponsor Foundation for Advancing Science Technology Education and Research
Collaborators: Boehringer Ingelheim
Conditions Rheumatoid Arthritis (RA), SSc-Systemic Sclerosis
Enrollment 800 participants
Start Date 2026-09-30
Primary Completion 2027-03-30 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-09-30